Introduction
The updated overall survival (OS) analysis from the phase 3 CARTITUDE-4 trial represents a watershed moment, demonstrating that a single infusion of the BCMA-directed CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) significantly improves OS compared to standard care in lenalidomide-refractory multiple myeloma after 1–3 prior lines ( 1 ). As the first phase 3 CAR-T trial in myeloma to show a statistically significant OS benefit, it solidifies cilta-cel as a transformative option and compels the field to confront pressing questions about moving CAR-T earlier, alongside implications for trial design, safety, and equity.
Core contributions and clinical value
The trial’s paramount contribution is confirming a significant OS advantage (HR 0.55, p=0.0009) at 33.6 months median follow-up, building on its prior progression-free survival (PFS) benefit ( 2 ). The no-crossover design provides an uncontaminated survival assessment. High rates of minimal residual disease negativity (62% at 10 -5 ) and delayed symptom worsening underscore that deep, durable responses translate into survival and quality-of-life gains. The data support considering cilta-cel as early as first relapse in lenalidomide-refractory patients, suggesting a potential shift from the paradigm of reserving CAR-T for later lines, while the current evidence does not yet mandate definitive practice change. Consistent benefit across most subgroups, including high-risk cytogenetics, strengthens its broad potential in earlier relapse.
Critical evaluation and methodological considerations
Several limitations necessitate careful interpretation. The static control arm (PVd/DPd), while appropriate at design, may magnify cilta-cel’s benefit relative to newer regimens, underscoring the need for head-to-head trials against contemporary standards ( 3 – 5 ). Specifically, the control regimens (pomalidomide, bortezomib, dexamethasone or daratumumab, pomalidomide, dexamethasone) represent standard options at the time of trial design but have since been supplemented by novel combinations, potentially overestimating the relative benefit of cilta-cel. Early separation of PFS/OS curves highlights a critical, modifiable real-world factor: effective bridging therapy. However, the trial did not standardize bridging regimens, leaving uncertainty about how much of the early benefit is attributable to bridging versus cilta-cel itself; future protocols should prioritize standardized, potent bridging strategies.
The no-crossover design, while scientifically clean for OS estimation, creates ethical and practical tensions by denying post-progression access to cilta-cel for control-arm patients, emphasizing the balance between regulatory endpoints and patient access within trials. Although this design provides an unbiased estimate of OS, it raises ethical concerns regarding patient access to a potentially life-prolonging therapy after progression, highlighting a tension between rigorous endpoint assessment and patient welfare.
Safety signals demand long-term vigilance. While grade 3–4 cytopenias were common, reports of secondary hematological malignancies, including CAR-positive T-cell lymphoma, warrant careful monitoring ( 6 ). However, the absolute risk appears low based on current follow-up, and causality remains uncertain given patients’ prior exposure to multiple lines of therapy. Potential mechanisms range from insertional mutagenesis to immune selection pressure ( 7 ). This risk necessitates lifetime monitoring guidelines, explicit informed consent, and translational research to identify predisposing factors, aligning with recent regulatory communications. Toxicity assessment per consensus grading ( 8 ).
Generalizability and equity gaps exist. The trial population (good ECOG status, organ function) may not reflect older, frailer patients with comorbidities seen in practice. Lack of racial and socioeconomic diversity limits understanding of how these factors influence outcomes. Given that CAR-T access is shaped by cost, geography, and systemic biases, the findings apply most directly to a subset, highlighting significant implementation challenges.
Interdisciplinary and systemic perspectives
Biologically, earlier CAR-T use may capitalize on better T-cell fitness and a less immunosuppressive microenvironment, a hypothesis supported by lymphoma trends. Translational studies correlating pre-infusion T-cell phenotypes and microenvironment signatures with outcomes are crucial for refining selection ( 7 , 9 , 10 ).
From a health systems perspective, logistical and financial challenges are monumental. The high upfront cost (>$400,000), as highlighted in recent cost-effectiveness analyses ( 11 ), need for specialized centers, and long-term monitoring create profound barriers; disparities in access by race, insurance, and geography have been documented ( 12 ). Innovative models are urgently needed, such as hub-and-spoke networks for expanded reach, investment in decentralized manufacturing to reduce costs/delays, and condition-based reimbursement tied to durable response. Without systemic innovation, earlier CAR-T will exacerbate global oncology inequities.
Cross-disciplinary insight from solid tumors is informative. The shift of immune checkpoint inhibitors into earlier lines in uro-oncology, grappling with similar cost, biomarker, and toxicity questions, offers lessons. Biomarker development (e.g., PD-L1, MSI) has been key for optimizing checkpoint inhibitor sequencing; similar pragmatic biomarker development is needed for BCMA-directed therapies in myeloma.
Future directions and conclusions
CARTITUDE-4 mandates critical next steps: prospective trials directly comparing cilta-cel with contemporary standards; exploring efficacy in newly diagnosed high-risk myeloma; and non-negotiable biomarker development to identify patients with the optimal benefit-risk ratio. Real-world evidence must capture data from older, diverse, and comorbid populations.
On a policy level, multidisciplinary collaboration is required to streamline manufacturing, develop sustainable financing, and create equitable access pathways. Guidelines must evolve to include CAR-T as an early option, coupled with investments in infrastructure and training for toxicity management and long-term follow-up.
In conclusion, CARTITUDE-4 is a landmark trial demonstrating that CAR-T can significantly prolong survival when used earlier in the relapsed/refractory continuum, providing evidence to advocate for considering a paradigm shift rather than mandating an immediate change in practice ( 1 , 2 ). However, translating this evidence into equitable practice hinges on overcoming substantial hurdles: optimizing patient selection and bridging therapy, mitigating long-term risks like secondary malignancies, and addressing systemic cost and access barriers. Realizing the promise of cellular immunotherapy for all patients requires rigorous science, honest dialogue on resource allocation, and compassionate policymaking.
Edited by: Sharon R Pine , University of Colorado Anschutz Medical Campus, United States
Reviewed by: Abhinava Mishra , University of Louisville, United States
Author contributions
C-qZ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Supervision, Writing – original draft, Writing – review & editing. S-QZ: Conceptualization, Data curation, Formal analysis, Investigation, Supervision, Writing – original draft, Writing – review & editing. Q-HK: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1 Einsele H San-Miguel J Dhakal B Touzeau C Leleu X van de Donk NW . Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial . Lancet Oncol . ( 2026 ) 27 ( 2 ): 254–68 . doi: 10.1016/S1470-2045(25)00653-9 41519141
2 San-Miguel J Dhakal B Yong K Spencer A Anguille S Mateos MV . Cilta-cel or standard care in lenalidomide-refractory multiple myeloma . N Engl J Med . ( 2023 ) 389 ( 4 ): 335–47 . doi: 10.1056/NEJMoa2303379 37272512
3 Rodriguez-Otero P Ailawadhi S Arnulf B Patel K Cavo M Nooka AK . Ide-cel or standard regimens in relapsed and refractory multiple myeloma . N Engl J Med . ( 2023 ) 388 ( 11 ): 1002–14 . doi: 10.1056/NEJMoa2213614 36762851
4 Usmani SZ Quach H Mateos MV Landgren O Leleu X Siegel D . Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study . Blood Adv . ( 2023 ) 7 ( 14 ): 3739–48 . doi: 10.1182/bloodadvances.2023010026 PMC10368773 37163358
5 Dimopoulos MA Beksac M Pour L Delimpasi S Vorobyev V Quach H . Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma . N Engl J Med . ( 2024 ) 391 ( 5 ): 408–21 . doi: 10.1056/NEJMoa2403407 38828951
6 Ghilardi G Fraietta JA Gerson JN Van Deerlin VM Morrissette JJD Caponetti GC . T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy . Nat Med . ( 2024 ) 30 ( 4 ): 984–9 . doi: 10.1038/s41591-024-02826-w 38266761
7 van de Donk NWCJ Themeli M Usmani SZ . Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma . Blood Cancer Discov . ( 2021 ) 2 : 302–18 . doi: 10.1158/2643-3230.bcd-20-0227 . PMID: 34386775 PMC8357299
8 Lee DW Santomasso BD Locke FL Ghobadi A Turtle CJ Brudno JN . ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells . Biol Blood Marrow Transplant . ( 2019 ) 25 ( 4 ): 625–38 . doi: 10.1016/j.bbmt.2018.12.758 . PMID: 30592986 PMC12180426
9 Martin T Usmani SZ Berdeja JG Agha M Cohen AD Hari P . Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up . J Clin Oncol . ( 2023 ) 41 ( 6 ): 1265–74 . doi: 10.1200/JCO.22.00842 . PMID: 35658469 PMC9937098
10 Raje N Berdeja J Lin Y Siegel D Jagannath S Madduri D . Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma . N Engl J Med . ( 2019 ) 380 ( 18 ): 1726–37 . doi: 10.1056/NEJMoa1817226 . PMID: 31042825 PMC8202968
11 Yamamoto C Minakata D Yokoyama D Furuki S Noguchi A Koyama S . Cost-effectiveness of anti-BCMA chimeric antigen receptor T cell therapy in relapsed/refractory multiple myeloma . Transplant Cell Ther . ( 2024 ) 30 ( 1 ): 118.e1–118.e15 . doi: 10.1016/j.jtct.2023.10.001 . PMID: 37802181
12 Warnakulasuriya H Tiwari R . Racial and socioeconomic healthcare disparities in access to chimeric antigen receptor T (CAR-T) cell therapy for blood cancers . Cancer Med . ( 2026 ) 15 : e71457 . doi: 10.1002/cam4.71457 . PMID: 41651454 PMC12880879